Aileron Therapeutics, Inc.: Clinical stage oncology company conducting 3 clinical trials for its lead candidate, ALRN-6924, a first-in-class/best-in-class drug that targets the p53 pathway. ALRN-6924 is from the Stapled peptide platform and is the only clinical drug candidate that binds equipotently to both of the p53 suppressor proteins, MDMX and MDM2. This company has now initiated of a Phase 1 / 1b in Acute Myeloid Leukemia (AML) and a Phase 2a in Peripheral T-Cell Lymphoma.
Based in...
US - New England
Clinical Stage
Phase l or ll
Disease Space
Public, USA
Market Cap
Therapeutic Modalities
Platform Technology
490 Arsenal Way
Suite 210
Cambridge, MA 02472
United States

Top 10 Holders of Aileron Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Armistice Capital LLC 3.72 1,460,620 1.85 Stakes 12/31/19
Renaissance Technologies LLC 4.98 1,383,881 1.76 13F 6/30/20
Banco Bilbao Vizcaya Argentaria SA 3.07 854,250 1.08 13F 6/30/20
BBVA Asset Management SA SGIIC 3.07 853,784 1.08 Funds 6/30/20
DAFNA Capital Management LLC 1.62 450,000 0.57 13F 6/30/20
William Blair & Co. LLC 0.86 238,544 0.30 13F 6/30/20
The Vanguard Group, Inc. 0.82 227,654 0.29 Funds 8/31/20
Vanguard Group, Inc. (Subfiler) 0.81 224,318 0.28 13F 6/30/20
Geode Capital Management LLC 0.51 141,772 0.18 13F 6/30/20
Traynor Capital Management, Inc. 0.36 100,000 0.13 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.